About 10X Genomics Inc
- Industry: Life Sciences Tools & Services
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.10xgenomics.com/
Frequently Asked Questions
What is the 52-week range for TXG?
The 52-week high is $95.16 and the 52-week low is $11.16.
What is the P/E ratio for TXG?
The P/E ratio data is currently unavailable.
What is the dividend yield for TXG?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -9.33%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -12.18%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.59.
Analyst Recommendation Trends
Wall Street analyst consensus for TXG over the last few months:
Latest TXG News
10 Stocks Rally as Rate Hike Bets Collapse on Weak September Jobs
Entegris, Rocket and KLA led premarket gains after September payrolls rose just 29,000 vs. 90,000 expected, cutting bets on a Fed rate hike.
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis. For more than a decade, 10x has pioneered technologies that catalyzed the single cell and spatial biology revolutions, changing how researchers measure and understand biology. Sentira extends t
10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the first commercial shipments of Atera, marking a major milestone for a platform that will redefine what's possible in spatial biology.
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90
Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.
10x Genomics Begins Commercial Shipments Of Its Transcriptome Analysis Tool Atera
Atera is moving into the hands of researchers around the world, from those scaling existing spatial programs to researchers exploring spatial biology for the first time, across discovery, translational and biopharma
10x Genomics Launches NVIDIA-Accelerated Sentira Spatial Analysis, Cutting Spatial Data Processing Times From Hours To Minutes
Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcherPLEASANTON, Calif.,
10x Genomics (TXG) Stock Is Up, What You Need To Know
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on the company with a Buy rating.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index and the State Street Hea
First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls
First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110
Argus Research analyst John Eade initiates coverage on 10x Genomics (NASDAQ:TXG) with a Buy rating and announces Price Target of $110.
What Needs To Be True To Buy Twist Bioscience Stock Now?
A $10,000 holding in Twist Bioscience (TWST) a year ago is worth about $66,600 today. The same sum in the S&P 500 would be worth about $11,700. The company sells made-to-order DNA to drug makers and research labs. Its sales grow fast, but it still loses money. The price now counts on that growth lasting and the losses ending. How much has to go right for that price to hold.
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at 10x Genomics (NASDAQ:TXG) and the best and worst performers in the life sciences tools & services industry.
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
10x Genomics (TXG) Stock May Look Pricey As Oncology AI News Lands
10x Genomics has delivered an unusually strong share price run over the past year, which puts a spotlight on whether the current valuation lines up with its sales base. With the stock now well above where it traded in prior years, investors are increasingly asking how much of the business story is already reflected in the price. Over the last 12 months, the stock has returned roughly 4.9x, which raises the question of how much future sales progress is already being assumed in the current...
The ARK Trade Watch: Cathie Wood Cuts Crypto Exposure, Then Reverses Course On CoreWeave
Cathie Wood's ARK Invest funds made a broad move out of crypto-linked assets during the week, led by the sale of more than 1.5 million shares of the ARK 21Shares Bitcoin ETF.
3 Russell 2000 Stocks That Fall Short
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Cathie Wood Makes Striking Switch Between AI Stock Giants
One portfolio shift stands out from Wood's latest moves
Radiant Logistics, Waystar, Forgent Power Solutions And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell, but Radiant Logistics surged 17.8% after beating Q4 estimates. Waystar, Telix and Forgent also posted strong gains.
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share
10x Genomics To Incorporate Lunit's AI-Powered Pathology Platform Into Its Oncology Biomarker Discovery Workflow
Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.
Multiomics Market Report Now Available — See Why Spatial Omics Is Set to Outgrow Single-Cell as the Field's Next Growth Driver
578-Page Report Forecasts Market Growth from $3.18B (2026) to $5.7B by 2031, Profiling 10x Genomics, Thermo Fisher, Illumina, Oxford Nanopore, Bruker, and 14 Other Key Players Multiomics Market Multiomics Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Multiomics Market by Offerings, Method, Technology, Workflow, Application, Competition - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Global Multiomics Market to Reach USD 5.70 Billion by 2031, Driven by Pre
3 Inflated Stocks with Open Questions
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Saxonov Serge | -2,800 | $82.365 | $230,622 |
| 2026-09-22 | Saxonov Serge | -9,900 | $81.8254 | $810,071 |
| 2026-09-22 | Saxonov Serge | -9,300 | $80.9033 | $752,401 |
| 2026-09-22 | Saxonov Serge | -2,000 | $79.6195 | $159,239 |
| 2026-09-22 | Saxonov Serge | -1,000 | $78.2284 | $78,228 |
| 2026-09-22 | SULIMAN SHEHNAAZ | -1,222 | $82.2768 | $100,542 |
| 2026-09-22 | SULIMAN SHEHNAAZ | -2,270 | $81.6699 | $185,391 |
| 2026-09-22 | SULIMAN SHEHNAAZ | -1,325 | $80.8164 | $107,082 |
| 2026-09-22 | SULIMAN SHEHNAAZ | -614 | $79.5114 | $48,820 |
| 2026-09-22 | SULIMAN SHEHNAAZ | -292 | $78.1959 | $22,833 |
| 2026-09-09 | Taich Adam | -13,754 | $65.2574 | $897,550 |
| 2026-09-09 | Taich Adam | -31,428 | $64.3097 | $2,021,125 |
| 2026-09-09 | Taich Adam | -1,206 | $63.6774 | $76,795 |
| 2026-09-03 | STUELPNAGEL JOHN R | -6,174 | $62.6066 | $386,533 |
| 2026-09-03 | STUELPNAGEL JOHN R | -6,814 | $62.1082 | $423,205 |
| 2026-09-03 | STUELPNAGEL JOHN R | -7,012 | $60.6579 | $425,333 |
| 2026-09-01 | Saxonov Serge | -100 | - | - |
| 2026-08-26 | Saxonov Serge | -492 | $64.7465 | $31,855 |
| 2026-08-26 | Saxonov Serge | -6,494 | $63.9768 | $415,465 |
| 2026-08-26 | Saxonov Serge | -3,500 | $63.0229 | $220,580 |
| 2026-08-24 | Saxonov Serge | -18,545 | $63.0237 | $1,168,775 |
| 2026-08-24 | Taich Adam | -17,166 | $63.023 | $1,081,853 |
| 2026-08-24 | Hindson Benjamin J. | -13,818 | $63.0236 | $870,860 |
| 2026-08-24 | SULIMAN SHEHNAAZ | -1,646 | $63.9664 | $105,289 |
| 2026-08-24 | SULIMAN SHEHNAAZ | -561 | $62.7259 | $35,189 |
| 2026-08-20 | Saxonov Serge | -4,000 | - | - |
| 2026-08-14 | Teichmann Sarah A. | -2,273 | $57.15 | $129,902 |
| 2026-08-13 | Teichmann Sarah A. | -5,278 | $57.29 | $302,377 |
| 2026-08-11 | STUELPNAGEL JOHN R | -3,000 | $58.725 | $176,175 |
| 2026-08-11 | STUELPNAGEL JOHN R | -17,000 | $57.5812 | $978,880 |
| 2026-06-22 | Saxonov Serge | -1,661 | $36.1646 | $60,069 |
| 2026-06-22 | Saxonov Serge | -9,821 | $35.3159 | $346,837 |
| 2026-06-22 | Saxonov Serge | -9,991 | $34.2815 | $342,506 |
| 2026-06-22 | Saxonov Serge | -8,527 | $33.289 | $283,855 |
| 2026-06-04 | Teichmann Sarah A. | +8,829 | - | - |
| 2026-06-04 | SULIMAN SHEHNAAZ | +8,829 | - | - |
| 2026-06-04 | Kosaraju Sridhar | +8,829 | - | - |
| 2026-06-04 | MATEO ALAN | +8,829 | - | - |
| 2026-06-04 | Popovits Kimberly J | +8,829 | - | - |
| 2026-06-04 | STUELPNAGEL JOHN R | +8,829 | - | - |
| 2026-05-26 | Saxonov Serge | -10,718 | $24.7092 | $264,833 |
| 2026-05-22 | Saxonov Serge | -18,175 | $24.4415 | $444,224 |
| 2026-05-22 | Hindson Benjamin J. | -11,595 | $24.4415 | $283,399 |
| 2026-05-22 | Taich Adam | -15,098 | $24.4415 | $369,018 |
| 2026-04-14 | Saxonov Serge | -5,000 | $24.5568 | $122,784 |
| 2026-03-24 | Saxonov Serge | -5,000 | $19.5223 | $97,612 |
| 2026-03-23 | Saxonov Serge | -10,000 | $19.1297 | $191,297 |
| 2026-03-03 | Saxonov Serge | -2,750 | - | - |
| 2026-03-02 | Saxonov Serge | -1,860 | $23.1781 | $43,111 |
| 2026-03-02 | Saxonov Serge | -14,292 | $22.669 | $323,985 |
| 2026-02-26 | Saxonov Serge | +157,895 | - | - |
| 2026-02-26 | Hindson Benjamin J. | +88,816 | - | - |
| 2026-02-26 | Taich Adam | +106,579 | - | - |
| 2026-02-25 | Teichmann Sarah A. | -7,579 | $19.41 | $147,108 |
| 2026-02-23 | Saxonov Serge | -9,632 | $18.5764 | $178,928 |
| 2026-02-23 | Taich Adam | -8,968 | $18.5764 | $166,593 |
| 2026-02-23 | Hindson Benjamin J. | -7,826 | $18.5764 | $145,379 |
| 2026-01-05 | Saxonov Serge | -32,537 | - | - |
| 2026-01-05 | Saxonov Serge | -17,463 | - | - |
| 2026-01-05 | Saxonov Serge | +50,000 | $1.2 | $60,000 |
| 2025-11-24 | Taich Adam | -11,888 | $18.9983 | $225,852 |
| 2025-11-24 | Hindson Benjamin J. | -8,283 | $18.9983 | $157,363 |
| 2025-11-24 | Saxonov Serge | -13,261 | $18.9983 | $251,936 |